This review will cover the different treatment modalities of adult soft tissue sarcomas.
INTRODUCTION
Soft tissue sarcomas (STSs) are mesenchymal derived cancers which have more than 100 histological subtypes according to the most recent World Health Organization classification [1] . These tumors are rare and account for less than 1% of all adult malignancies [2] . In the USA 11,930 new cases of STS are diagnosed each year with 4870 deaths [3] . They arise from any part of the body, but the majority occur in the extremities (59.5%) undifferentiated unclassified sarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, and malignant peripheral nerve sheath tumor (MPNST) [1] . Painless mass is the most common clinical presentation. Tumor tends to grow locally along tissue planes, surrounded by a so-called pseudocapsule which contains malignant cells infiltrating adjacent tissues [1] ; therefore, the dissection along the pseudocapsule is contraindicated [5] .
The presence of distant metastases at the time of initial diagnosis is rare [6] . The most common pattern of spread is via blood, typically to the lung [6] . Lymph node metastases are infrequent (less than 3%) [7] , with the exception of certain histologies such as epithelioid sarcoma, rhabdomyosarcoma, angiosarcoma, and clear cell sarcoma [7] . Pretreatment evaluation includes magnetic resonance imaging of the primary site and chest computed tomography [5] . Tumor stage is the most important prognostic factor. The most recent, 7th edition of the American Joint Committee on Cancer (AJCC) system is the most widely used. It incorporates tumor size, depth, lymph node involvement, distant metastases, and histologic grade in determining four stage groups with different outcome [8] . Thus, reported 5-year overall survival (OS) rates for stages I, II, and III were 90%, 81%, and 56%, respectively [8] . In addition to tumor stage, other prognostic factors are anatomic site, histologic subtype, age, and surgical margins [9] . The management of patients with STS requires a multimodality treatment provided by an expert multidisciplinary team working in a reference center or within a reference network [5] . Thereby, clinical practice guidelines recommend referral of all patients with suspected sarcoma to a reference center for appropriate diagnostic and optimal outcome [5] . In fact, Gustafson et al. [10] demonstrated that patients treated at a tumor center have better outcome as compared to patients who
were not referred to a tumor center or those who were referred to a tumor center after surgery. In their series local recurrence was 2.4 times higher when patients were treated outside of a reference center and 1.3 times higher if the patients were referred to a tumor center after surgery [10] .
The present review covers different treatment modalities for adult STSs based on recent clinical practice guidelines, data from clinical trials, and meta-analysis. We have excluded from this review extraskeletal Ewing sarcoma, embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, and gastrointestinal stromal tumors (GIST), as they belong to separate therapeutic approaches. This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
TREATMENT OF LOCALIZED DISEASES

Surgery
Surgery is the standard treatment of localized STS [5] and consists of a wide surgical resection, with total en bloc excision of the primary tumor, the biopsy site, and a rim of normal tissues around the tumor [11] . Dissection along the pseudocapsule is strictly prohibited [5] . Resection margins represent the main risk factor for local recurrence [ Because lymph node involvement is uncommon in STS, systematic regional node dissection is not recommended [5] . Node dissection should be performed only if there is evidence of lymph node disease [7] . In this setting, it has been reported that radical lymphadenectomy for isolated regional lymph node metastases provides long-term survival:
46% 5-year survival, with a median survival of 16.3 months versus 4.3 months in patients not treated with lymph node dissection [7] . However, it is unclear if treatment of occult node metastases based on earlier detection of metastatic nodes by sentinel lymph node biopsy or positron emission tomography would improve outcome in histologies with higher frequency of lymph nodes metastasis including epithelioid sarcoma, rhabdomyosarcoma, angiosarcoma, synovial sarcoma, and clear cell sarcoma [18, 19] .
Surgery alone with negative margins provides a local control rate close to 93% in a selected subset of patients (superficial and low grade tumors that are 5 cm or less in size, and selected truly intracompartmental tumor) [20, 21] . However, some patients are at high risk of recurrence and will require complementary treatment [22] .
Radiotherapy
The benefit of RT as adjuvant treatment to limb-sparing surgery has been initially addressed in comparison with radical surgery.
These studies have shown that RT, when combined with conservative surgery, provides similar rates of local control to those achieved with amputation [14] . Since the publication of these results, amputation as a primary therapy has largely been abandoned for most patients [15] . So, with the emergence of RT in the management of STSs, two randomized trials using different modalities of radiation therapy (external beam RT (EBRT) [23] [9] . Re-excision seems to be the best option for favorable outcome in patients with marginal resection. Zagars et al. [27] reported local control rates of 85%, 85%, and 82% at 5, 10, and 15 years, respectively, for patients who underwent re-resection versus 78%, 73%, and 73%, respectively, for patients who did not undergo re-resection [27] . Therefore, re-excision must be strongly considered in case of R2 or R1 resections, if adequate margins can be achieved without major morbidity [5, 13] .
Postoperative RT improves local control in patients with marginal excisions and in those with residual tumor cells after re-excision. The 10-year local recurrence rates for patients treated with surgery alone and patients treated with combined surgery and RT was 17% (95% CI 8-32%) versus 53% (95% CI 25-75%), respectively (P = 0.005), in patients with marginal resection and 84% in the RT group versus 37% in the no-RT group (P = 0.001) in patients with residual cells after re-excision [28] .
Several independent adverse prognostic factors for local recurrence have been reported The optimal timing of radiation therapy has yet to be defined. The treatment should be individualized and the best option should be discussed in a multidisciplinary tumor board. A total dose of 50 Gy in 1.8-to 2-Gy fractions is recommended, possibly with a boost up to 66 Gy, depending on presentation and resection margins [5] .
Brachytherapy is another modality of RT in which a radiation source is placed inside the targeted area. [54] . This option could be considered in chemosensitive STS using multi-agent chemotherapy with anthracycline, ifosfamide with or without dacarbazine given to the higher response rate achieved by these protocols [55, 56] .
In the absence of randomized controlled trials to define the most effective strategy to manage locally advanced STS, there is no consensus among reference centers and therapeutic options are usually influenced by the availability of technical equipment and the institutional experience.
LOCALLY RECURRENT SOFT TISSUE SARCOMAS
About 15% of patients with STS will develop a local relapse in spite of effective local therapy for the primary lesion [57, 58] . Local recurrence occurs mostly within the first 2 years [57] . The outcome is poorer as compared to primary cases because of the increased risk of distant failure [59] . Wide surgical resection is the cornerstone of treatment [5] . Radiation therapy improves local control and should be considered [5, 13] Further trials are needed to assess the potential benefit and the safety profile of this new treatment in this specific population of patients.
TREATMENT OF METASTATIC SOFT TISSUE SARCOMAS
Management of metastatic STS is a challenging problem. Treatment is essentially palliative and the potential for cure decreases drastically. The reported median OS is about 12-18 months [63, 64] . However, about 5-8% of patients are alive progression-free 5 years after the initial diagnosis of metastasis, and most will not relapse later [65] . Chemotherapy is the mainstay of treatment in the metastatic setting. However, surgery of metastatic lesions if feasible should be offered since it provides long-term survival [66] . Reported median survival after complete excision of isolated lung metastases is 33-35 months versus 11-13 months in patients with non-surgical treatment [66, 67] . Patients with extrapulmonary metastases can also achieve significant long-term survival when a complete resection is possible for both the pulmonary and extrapulmonary metastases [66] . Unfortunately most patients are not amenable to ablative approaches. In these instances, treatment is palliative and is based on systemic chemotherapy. of 10% for the lower-dose treatment and 25% for the higher dose [71] . Therefore, the most commonly used scheme is 3 g/m 2 ifosfamide administered on days 1, 2, and 3, repeated every 3 weeks. A role for high-dose ifosfamide (14-18 mg/m 2 ) has been suggested in the treatment of metastatic synovial sarcoma [74] .
A head-to-head comparison of doxorubicin and ifosfamide in first-line treatment for patients with advanced and/or metastatic soft tissue sarcoma found no differences in PFS, OS, or response rates. However, grade 4 toxicities were more frequent in the ifosfamide arms [75] .
This finding supports the use of single-agent doxorubicin as the treatment of choice in metastatic STS, though ifosfamide is a reasonable alternative if patients cannot be treated with an anthracycline initially.
Multi-agent chemotherapy with doxorubicin plus ifosfamide in first-line treatment of metastatic STS results in higher overall response rate (26.5% versus 13.6%), but without survival advantage over single agent doxorubicin [64] . Therefore, combination therapy may be considered only when a tumor response is felt to be potentially advantageous [5] .
Ifosfamide may be used after failure of anthracycline-based chemotherapy in patients who did not progress on it previously [5, 13 ].
The median survival of patients exposed to ifosfamide in second-line treatment after doxorubicin failure is in the range of 35-45 weeks with a median time-to-progression of 6-14 weeks [70, 71] . For patients who have already received standard-dose ifosfamide, high-dose ifosfamide is a reasonable option [76, 77] .
Other conventional cytotoxic drugs such as dacarbazine [78, 79] Eribulin has been shown to improve OS by 2 months (13.5 versus 11.5 months) as with the well-characterized toxicities of both drugs [94] . Several other multi-agent combinations of active drugs in STS have been investigated. Doxorubicin plus dacarbazine leads to a response rate of 30% without a benefit in terms of OS [95, 96] . This regimen is a reasonable choice in the first-line treatment of leiomyosarcoma which is less sensitive to ifosfamide [5] , or in patients in whom ifosfamide is contraindicated. 
TARGETED THERAPIES
Pazopanib is an oral kinase inhibitor targeting VEGF-R, PDGFR, and c-KIT. It is the first and the only antiangiogenic drug approved for the treatment of refractory non-adipocytic soft tissue sarcoma [99] . After promising results in a phase II trial [100] , a large randomized phase III trial (PALETTE) was conducted. The PALETTE trial showed a benefit in terms of PFS averaging 3 months (median 4.6 versus 1.6 months; P\0.0001) for pazopanib given up to progression in refractory non-adipocytic soft tissue sarcoma patients [101] . However, no significant benefit in terms of OS was found; the median OS in patients treated with pazopanib was 12.5 versus 10.7 months in the placebo arm (P = 0.25). This was explained by the use of post-trial systemic therapy with other agents in the placebo group. The objective response rate was 6% for pazopanib versus 0% for placebo, with 67% stable diseases in the pazopanib arm versus 38% in the placebo arm [101] . In the PALETTE trial, adipogenic tumors were excluded on the basis of the lack of activity of pazopanib in this histology subtype in the phase II trial. However, an ongoing trial (ClinicalTrials identifier NCT1506596) will assess pazopanib's activity in adipocytic sarcomas including dedifferentiated, myxoid-round cell, pleomorphic, and mixed type [102] , since these genetic subtypes have vascular patterns and may theoretically respond to pazopanib [102] . The most common adverse events of pazopanib were fatigue, diarrheas, nausea, weight loss, and hypertension [101] . Retrospective analysis on pooled data from the previously cited phase II and III EORTC trials showed that good performance status, low/ intermediate grade of the primary tumor, and a normal hemoglobin level at baseline were advantageous for long-term outcome.
Long-term responders were defined as patients with PFS of at least 6 months (36%), long-term survivors as patients who survived for at least 18 months (34%) [103] .
There is some evidence of the activity of several molecular targeted agents, including tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors in selected histologies. However, these agents are not approved by regulatory authorities for the treatment of STS and should be preferably used within clinical trials [13] .
Cediranib, a potent inhibitor of VEGFR receptors, has shown activity in alveolar soft part sarcoma (ASPS) with a disease control rate at 24 weeks of 84% in a phase II trial [104] .
Sunitinib, an oral angiogenesis inhibitor, achieved promising results in patients with solitary fibrous tumors (n = 10) with 70% objective response and response duration of more than 6 months in five cases [105] . Sunitinib has also shown clinical efficacy in five of nine patients with ASPS treated with sunitinib 37.5 mg daily, continuously [106] .
Crizotinib, an orally ATP-competitive inhibitor of the ALK and MET tyrosine kinases, has shown antitumor activity in ALK-rearranged inflammatory myofibroblastic tumor [107] . Determining the optimal trial design and identifying the predictive biomarkers are crucial steps for the development of these drugs. 
CONCLUSIONS
